Akcea and Ionis Announce Initiation of CARDIO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with TTR-mediated Amyloid Cardiomyopathy

NEXT STORY
Global In-Vitro Diagnostics (IVD) Market Report, 2019-2025 – Advent of NGS has Created a Significant Opportunity for Advances in IVD Tests
PREV STORY
Press release Oncology Venture issues 287,500 new shares in connection with a debt conversion
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

3D Signatures Inc. Reports Third Quarter 2017 Financial Results

TORONTO, May 31, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the ...

author_avatar
NASDAQ Market News

TESARO Announces Participation at Goldman Sachs 38th Annual Global Healthcare Conference

WALTHAM, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical ...

author_avatar
NASDAQ Market News

TESARO to Announce Second-Quarter 2017 Financial Results on August 8, 2017

WALTHAM, Mass., July 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its ...

author_avatar
NASDAQ Market News